CN1188170C - 含前列腺素类化合物和苄醇的溶液 - Google Patents
含前列腺素类化合物和苄醇的溶液 Download PDFInfo
- Publication number
- CN1188170C CN1188170C CNB998062677A CN99806267A CN1188170C CN 1188170 C CN1188170 C CN 1188170C CN B998062677 A CNB998062677 A CN B998062677A CN 99806267 A CN99806267 A CN 99806267A CN 1188170 C CN1188170 C CN 1188170C
- Authority
- CN
- China
- Prior art keywords
- benzylalcohol
- prostaglandin
- solution
- concentration
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 title claims abstract description 285
- 235000019445 benzyl alcohol Nutrition 0.000 title claims abstract description 95
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 44
- 229940094443 oxytocics prostaglandins Drugs 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 229960004217 benzyl alcohol Drugs 0.000 claims description 93
- 239000000243 solution Substances 0.000 claims description 69
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 49
- 238000002360 preparation method Methods 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 23
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 21
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 239000003513 alkali Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 229960000281 trometamol Drugs 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 9
- ABYGSZMCWVXFCQ-UHFFFAOYSA-N 4-propylheptane Chemical compound CCCC(CCC)CCC ABYGSZMCWVXFCQ-UHFFFAOYSA-N 0.000 abstract description 2
- 229960004280 dinoprost tromethamine Drugs 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 230000008569 process Effects 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940090213 lutalyse Drugs 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940127293 prostanoid Drugs 0.000 description 2
- 150000003814 prostanoids Chemical class 0.000 description 2
- MCSJGXLZPITMIH-UHFFFAOYSA-N 2-aminobutane-1,1,1-triol Chemical class CCC(N)C(O)(O)O MCSJGXLZPITMIH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 229960003395 carboprost Drugs 0.000 description 1
- DLJKPYFALUEJCK-MRVZPHNRSA-N carboprost Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O DLJKPYFALUEJCK-MRVZPHNRSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000029860 luteolysis Effects 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- UTZNELIJGYWMKS-UHFFFAOYSA-N phenylmethanol;hydrate Chemical compound O.OCC1=CC=CC=C1 UTZNELIJGYWMKS-UHFFFAOYSA-N 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (22)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/094,985 US6187818B1 (en) | 1998-06-17 | 1998-06-17 | Prostaglandins formulation and process |
US09/094,985 | 1998-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1301178A CN1301178A (zh) | 2001-06-27 |
CN1188170C true CN1188170C (zh) | 2005-02-09 |
Family
ID=22248341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998062677A Expired - Lifetime CN1188170C (zh) | 1998-06-17 | 1999-06-08 | 含前列腺素类化合物和苄醇的溶液 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6187818B1 (zh) |
EP (1) | EP1085907B1 (zh) |
JP (1) | JP4472175B2 (zh) |
KR (1) | KR100608176B1 (zh) |
CN (1) | CN1188170C (zh) |
AT (1) | ATE263576T1 (zh) |
AU (1) | AU752047B2 (zh) |
CA (1) | CA2331284C (zh) |
DE (1) | DE69916266T2 (zh) |
DK (1) | DK1085907T3 (zh) |
ES (1) | ES2219036T3 (zh) |
HK (1) | HK1036413A1 (zh) |
NZ (1) | NZ508947A (zh) |
PT (1) | PT1085907E (zh) |
WO (1) | WO1999065527A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0200258A2 (hu) | 1999-03-05 | 2002-05-29 | The Procter & Gamble Co. | C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
CN108078998B (zh) * | 2017-11-23 | 2018-09-21 | 宁波三生生物科技有限公司 | 一种氨基丁三醇前列腺素F2α注射液及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3885041A (en) * | 1970-12-28 | 1975-05-20 | Searle & Co | Antiinflammatory use of prostaglandins |
US3917864A (en) | 1973-02-12 | 1975-11-04 | Sultanali M M Karim | Use of prostaglandins E and F for induction of labor |
US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
EP0268066A3 (en) | 1986-10-17 | 1990-07-11 | Syntex (U.S.A.) Inc. | Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists |
AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
-
1998
- 1998-06-17 US US09/094,985 patent/US6187818B1/en not_active Expired - Lifetime
-
1999
- 1999-06-08 CA CA002331284A patent/CA2331284C/en not_active Expired - Lifetime
- 1999-06-08 AU AU50796/99A patent/AU752047B2/en not_active Expired
- 1999-06-08 ES ES99935286T patent/ES2219036T3/es not_active Expired - Lifetime
- 1999-06-08 DE DE69916266T patent/DE69916266T2/de not_active Expired - Lifetime
- 1999-06-08 JP JP2000554404A patent/JP4472175B2/ja not_active Expired - Lifetime
- 1999-06-08 CN CNB998062677A patent/CN1188170C/zh not_active Expired - Lifetime
- 1999-06-08 DK DK99935286T patent/DK1085907T3/da active
- 1999-06-08 EP EP99935286A patent/EP1085907B1/en not_active Expired - Lifetime
- 1999-06-08 NZ NZ508947A patent/NZ508947A/en not_active IP Right Cessation
- 1999-06-08 KR KR1020007014321A patent/KR100608176B1/ko not_active IP Right Cessation
- 1999-06-08 PT PT99935286T patent/PT1085907E/pt unknown
- 1999-06-08 WO PCT/US1999/011808 patent/WO1999065527A1/en active IP Right Grant
- 1999-06-08 AT AT99935286T patent/ATE263576T1/de active
-
2001
- 2001-10-24 HK HK01107418A patent/HK1036413A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2331284C (en) | 2009-09-22 |
WO1999065527A1 (en) | 1999-12-23 |
AU752047B2 (en) | 2002-09-05 |
DK1085907T3 (da) | 2004-06-21 |
CN1301178A (zh) | 2001-06-27 |
PT1085907E (pt) | 2004-08-31 |
HK1036413A1 (en) | 2002-01-04 |
NZ508947A (en) | 2003-05-30 |
DE69916266T2 (de) | 2005-03-10 |
KR100608176B1 (ko) | 2006-08-04 |
US6187818B1 (en) | 2001-02-13 |
JP2002518348A (ja) | 2002-06-25 |
CA2331284A1 (en) | 1999-12-23 |
EP1085907B1 (en) | 2004-04-07 |
DE69916266D1 (de) | 2004-05-13 |
AU5079699A (en) | 2000-01-05 |
JP4472175B2 (ja) | 2010-06-02 |
EP1085907A1 (en) | 2001-03-28 |
ES2219036T3 (es) | 2004-11-16 |
ATE263576T1 (de) | 2004-04-15 |
KR20010052944A (ko) | 2001-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1809376B (zh) | 装在药物容器中的稳定的液体蛋白质制剂 | |
JP2007045841A (ja) | ヒト成長ホルモン水性製剤 | |
CN1331582A (zh) | 含有喷替酸的丙泊酚组合物 | |
JP2014208656A (ja) | 成長ホルモン製剤 | |
CZ2001743A3 (cs) | Primární obal a způsob jeho výroby | |
CN1416337A (zh) | 麻醉制剂 | |
CN1188170C (zh) | 含前列腺素类化合物和苄醇的溶液 | |
EP0900562A1 (en) | Lavage solution for intestinal tract | |
EP0199992A1 (en) | Adsorption-resistant peptide composition and use of benzalkonium or benzethonium chloride in the preparation thereof | |
KR100364466B1 (ko) | 주사용메스나용액,이의제조방법및이를함유하는약제 | |
JP6189437B2 (ja) | 注射用抗生物質製剤およびその使用方法 | |
CN1449289A (zh) | Oct制剂 | |
CN1041796C (zh) | 畜用长效抗痢混悬注射液及其制造方法 | |
CN1334725A (zh) | 普鲁泊福(2,6-二异丙基苯酚)和2,5-二-氧-甲基-1,4;3,6-双脱水-d-葡萄糖醇作为溶剂的胃肠外的溶液 | |
TWI631948B (zh) | 可注射型抗生素配方及其使用方法 | |
US9452155B2 (en) | Injectable antibiotic formulations and their methods of use | |
MXPA00012423A (en) | Solution comprising prostaglandins and benzyl alcohol | |
HU192990B (en) | Process for producing new compositions for injection containing 1-/2-hydroxy-ethyl/-2-methyl-5-nitro-imidazol | |
NZ613138B2 (en) | Injectable antibiotic formulations and their methods of use | |
CN1180315A (zh) | 含吲哚羧酸的胃肠外使用的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: PAH Free format text: FORMER OWNER: UPJOHN CO. Effective date: 20130619 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: ZOETIS PU CO., LTD. Free format text: FORMER NAME: PAH |
|
CP01 | Change in the name or title of a patent holder |
Address after: American New Jersey Patentee after: Zoetis Services LLC Address before: American New Jersey Patentee before: PAHPU LLC Address after: Michigan Patentee after: PHARMACIA & UPJOHN CO.,LLC Address before: Michigan Patentee before: PHARMACIA & UPJOHN Co. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130619 Address after: American New Jersey Patentee after: PAHPU LLC Address before: Michigan Patentee before: PHARMACIA & UPJOHN CO.,LLC |
|
ASS | Succession or assignment of patent right |
Owner name: SHUOTENG SERVICE LLC Free format text: FORMER OWNER: ZOETIS PU CO., LTD. Effective date: 20150730 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150730 Address after: New jersey, USA Patentee after: Zoetis Services LLC Address before: American New Jersey Patentee before: Zoetis Services LLC |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050209 |